In both in vitro and patient-derived xenograft models, treatment with the FTO inhibitor FB23-2 and the ferroptosis activator erastin enhanced the sensitivity of NPC cells to radiotherapy [55]. The gene discussed is FTO; the disease is nasopharyngeal carcinoma.